Cart
sales@molnova.com
DW71177
CAS No. 2241311-72-6
DW71177( —— )
Catalog No. M37566 CAS No. 2241311-72-6
DW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 188 | In Stock |
|
| 10MG | 302 | In Stock |
|
| 25MG | 607 | In Stock |
|
| 50MG | 918 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDW71177
-
NoteResearch use only, not for human use.
-
Brief DescriptionDW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.
-
DescriptionDW71177 is a novel [1,2,4]triazolo[4,3-a] quinoxaline-based potent and BD1-Selective BET inhibitor, and can be used for study of acute myeloid leukemia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2241311-72-6
-
Formula Weight384.48
-
Molecular FormulaC20H28N6O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NCCCCNC1=NC=2C=C(OC)C=CC2N3C1=NN=C3C)CC(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ali I, et al. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia. Eur J Med Chem. Published online December 16, 2023.?
molnova catalog
related products
-
SR-0813
SR-0813 is a potent and selective inhibitor of the YEATS domain in ENL/AF9, with an IC50 of 25 nM and EC50 of 205 nM for the ENL YEATS domain, and an IC50 of 311 nM and EC50 of 76 nM (CETSA) for the AF9 YEATS domain.
-
UNC?1021
UNC 1021 is a selective L3MBTL3 inhibitor (IC50 = 0.048 μM).
-
FHD-286
FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.
